METTL3 enhances NSD2 mRNA stability to reduce renal impairment and interstitial fibrosis in mice with diabetic nephropathy

• Published in: BMC nephrology Vol. 23; no. 1; pp. 124 - 14
• Main Authors: Tang, Weiming, Zhao, Yilin, Zhang, Hui, Peng, Ying, Rui, Zhilian
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.03.2022; BioMed Central; BMC
• Subjects: Analysis; Animal models; Animals; Blood pressure; Care and treatment; Creatinine; Cystatin C; Diabetes; Diabetes Mellitus; Diabetic nephropathies; Diabetic Nephropathies - genetics; Diabetic Nephropathies - metabolism; Diabetic nephropathy; Diagnosis; Disease; Feeds; Fibrosis; Gene expression; Glucagon; Glucose; Histone methyltransferase; Histone-Lysine N-Methyltransferase; Humans; Hyperglycemia; Hypertension; Insulin; Insulin secretion; Interstitial fibrosis; Kidneys; Laboratory animals; Males; Mesangial cells; Messenger RNA; Methyltransferases; Methyltransferases - genetics; Methyltransferases - metabolism; METTL3; Mice; mRNA stability; N6-methyladenosine; Nephrology; Nephropathy; NSD2; Patients; Proteins; Pulmonary fibrosis; Repressor Proteins; Risk factors; RNA modification; RNA Stability; RNA, Messenger - metabolism; Urine; YTHDF1; China; Beijing China; United States > US; Japan; Diabetic nephropathy; YTHDF1; Interstitial fibrosis; METTL3; NSD2

Nuclear receptor-binding SET domain protein 2 (NSD2) is a histone methyltransferase that has been demonstrated to regulate insulin secretion and glucose concentration. This study focused on the role of NSD2 in the renal impairment during diabetic nephropathy (DN). Serum NSD2 level in patients with D...